Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving hydrolase
Reexamination Certificate
2005-07-05
2005-07-05
Saucier, Sandra E. (Department: 1651)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving hydrolase
C435S219000, C530S384000
Reexamination Certificate
active
06913900
ABSTRACT:
A activator for prekallikrein includes isolated, purified, or substantially purified heat shock protein 90, a phosphate ion, and mixtures thereof. The prekallikrein activator is part of an in vitro system for activating prekallikrein in the absence of FXIIa. The system includes the activator, high-molecular weight kininogen, and zinc ions. A method for activating prekallikrein to produce kallikrein in the absence of FXIIa includes mixing prekallikrein with the activator and a composition comprising high molecular weight kininogen and zinc ions. A method for evaluating the activity of a test drug for the production of kallikrein comprises activating prekallikrein and determining the kallikrein produced. The activity (promoting or inhibiting ability) of the tested drug against the production of kallikrein in the absence of FXIIa can be easily measured. The test drug may be an analgesic, anti-allergy, anti-inflammatory drug.
REFERENCES:
patent: 4335203 (1982-06-01), Lasser
patent: 4598043 (1986-07-01), Svendsen
patent: 4882272 (1989-11-01), Scott et al.
patent: 4985254 (1991-01-01), Konishi
patent: 4985354 (1991-01-01), Toyomaki et al.
patent: 5013558 (1991-05-01), Konishi
patent: 5057324 (1991-10-01), Shibayama et al.
patent: 5560935 (1996-10-01), Konishi et al.
patent: 5599683 (1997-02-01), Nishikawa et al.
patent: 5648228 (1997-07-01), Nishikawa et al.
patent: 6117648 (2000-09-01), Shibayama et al.
patent: 0 341 209 (1989-11-01), None
patent: 0 637 632 (1991-01-01), None
patent: 697351 (1953-09-01), None
patent: 53101515 (1978-09-01), None
patent: 57077697 (1982-05-01), None
patent: 58035117 (1983-03-01), None
patent: 63-185398 (1991-01-01), None
patent: 7051097 (1995-02-01), None
patent: 7051098 (1995-02-01), None
Dreher D et al. 1995. Effects of oxidative stress and Ca2+ agonists on molecular chaperones in human umbilical vein endothelial cells. Electrophoresis. 16(7):1205-14.
Kaplan, A., et al., “Assessment of Hageman Factor Activation in Human Plasma: Quantification of Activated Hageman Factor-C1 Inactivator Complexes by an Enzyme-Linked Differential Antibody Immunosorbent Assay,”Blood, vol. 66, No. 3 (Sep.) 1985, pp. 636-641.
Gallimore, M.J., et al., “A Direct Chromogenic Peptide Substrate Assay for Hageman Factor (FXII),”J. of Fibrinolysis, 1(2), 1987, pp. 123-127.
Dumenco, L., et al., “Inhibition of the Activation of Hageman Factor (Factor XII) by Platelet Factor 4,”J. Lab. Clin. Med., 112(3), 1988, pp. 394-400.
Ghebrehiwet, B., “Identification of Functional Domans on GC1Q-R, a Cell Surface Protein That Binds to the Globular Heads of C1Q, Using Monoclonal Antibodies and Synthetic Peptides,”Hybridoma, 15(5):333-342, May 1996.
Kusumam, J., “Identification of the Zinc Dependent Endothelial Cell Binding Protein for High Molecular Weight Kininogen and FXII,”Proc Natl Acad Sci USA, 93:8552-8557, Aug. 1996.
Kaplan, A., “Binding of Activation of Kinin Forming Proteins on Vascular Endothelial Cells,”Immunopharmacology, 36:201-207, 1997.
Herwald et al., “Isolation and Characterization of the Kininogen-binding Protein p33 from Endothelial Cells,”J. Biological Chem., vol. 271, No. 22, pp. 13040-13047, May 31, 1966.
Ghebrehiwet et al., “Isolation cDNA Cloning, and Overexpression of a 33-kD Cell Surface Glycoprotein that Binds to the Globular ‘Heads’ of C1q,”J. Exp. Medicine, vol. 179, No. 6, pp. 1809-1821, Jun. 1994.
Motta Guacyara et al., “High molecular weight kininogen regulates prekallikrein assembly and activation and endothelial cells: A novel mechanism for contact activation”, BLOOD, vol. 91, No. 2, Jan. 15, 1998, pp. 516-528, XP-002262835.
Joseph Kusuman et al., “Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII”, Proceedings of the National Academy of Sciences of the United States, vol. 99, No. 2, Jan. 22, 2002, pp. 896-980, XP-002262836.
Joseph Kusumam
Kaplan Allen P.
Barnhart Lora E
Holland Law Firm, P.L.C.
Nippon Zoki Pharmaceutical Co. Ltd.
Saucier Sandra E.
LandOfFree
Plasma prekallikrein activation and kallikrein production assay does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Plasma prekallikrein activation and kallikrein production assay, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Plasma prekallikrein activation and kallikrein production assay will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3376995